Ono Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4 billion

Ono Pharmaceutical will acquire Deciphera Pharmaceuticals, which specializes in kinase inhibitor drugs to treat cancer, for $2.4 billion. Deciphera’s drug ripretinib, marketed as Quinlock, is approved in the US and 40 other countries to treat advanced gastrointestinal stromal tumors. The company expects to submit its drug candidate vimseltinib, which is meant to treat tenosynovial giant cell tumors, to US and European regulators this year.